Abstract
Neonates, particularly prematurely born neonates, are particularly vulnerable to enteric pathogens. Antibiotics are widely administered during pregnancy for off-label use and prevention, but the effect on neonatal physiology has not been well characterized. Maternally derived IgA provided in milk is a predominant protective measure in the intestinal lumen of the nursing offspring. The connection between the maternal intestine and mammary IgA responses has been observed, but understanding how clinical use of antibiotics effects mammary IgA remains unclear. Here we find that prenatal cephalosporin antibiotics, but not penicillins, decrease mammary IgA in dams, and limit the availability of IgA within the lumen of nursing offspring. Decreased IgA correlated with an outgrowth of commensal E. coli and increased colonization and translocation of pathogen E. coli. Moreover, antenatal cephalosporin administration was associated with increased mortality in a model of LOS that was associated with decreased mammary IgA. Futhermore, in a clinical cohort of at-risk infants, maternal broad spectrum antibiotic treatment, including cephalosporins, increased the risk of LOS in neonates in comparison to penicillin-based treatments. This was associated with reduced IgA in the milk, and we propose maternal administration of select antibiotics could disrupt mammary IgA, leading to increased risk of LOS in infants by allowing for pathogen colonization in the neonatal intestine.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the NIH DK134366 (KK).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of the University of Pittsburgh gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Revised order of figures for clarity
Data Availability
All data produced in the present study are contained in the manuscript, except for metagenomic sequencing files, which are available upon reasonable request to the authors and will be publically available in the NIH GenBank SRA database.
Metagenomic 16S sequences will be deposited and available in the NIH GenBank SRA database.
